Oculis Holding AG Ordinary shares

OCS

...

OCS: Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Show OCS Financials

All

Government

Consumer Interest

SEC Filings

ESG/Other

Congress Trading

Recent trades of OCS by members of U.S. Congress

No Congress Trading data for this ticker

Congress Trading Dashboard

Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by OCS's directors and management

No recent Insider Trading for this ticker

Insider Trading Dashboard

Corporate Lobbying

Government lobbying spending instances

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

U.S. Patents

New patents grants

No new patents for this ticker

U.S. Patents Dashboard

Government Contracts

Federal grants, loans, and purchases

No Government Contracts for this ticker

Government Contracts Dashboard

Twitter

Followers on OCS's company Twitter account

WallStreetBets

Number of mentions of OCS in WallStreetBets Daily Discussion

OCS News

Recent insights relating to OCS

CNBC Recommendations

Recent picks made for OCS stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in OCS

Corporate Flights

Flights by private jets registered to OCS